Aditxt, Inc. Share Price & Technical Analysis
ADTX · $0.52 (-57.38%)
Healthcare / Biotechnology
$0.52
-57.38%
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body natu…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-90% return in May, -17% avg return in past 3 year May month.
-288% return in 2026, -279% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -3% | -42% | -73% | -79% | -90% | – | – | – | – | – | – | – | -288% |
| 25 | -46% | -44% | -71% | -47% | -34% | -15% | -16% | -5% | -27% | -92% | -33% | -74% | -503% |
| 24 | -24% | -8% | -2% | -29% | -19% | -31% | -14% | -46% | -83% | -88% | -30% | -48% | -423% |
| 23 | 24% | -19% | -23% | -36% | 2% | -25% | -12% | 244% | -62% | -44% | -42% | 83% | 89% |
| 22 | -17% | -19% | 23% | -29% | -14% | -51% | 9% | -4% | -56% | -23% | -32% | -34% | -250% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Oversold
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions. Further, it offers Adivir for commercial development of products to address significant unmet needs in infectious disease and population health; and Adifem address critical unmet needs in women health. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$89.45K
P/E ratio
—
52W high
$53,454
52W low
$0.47
Volume
1,27,43,446
Beta
0.75
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Aditxt, Inc. share price today?
- Aditxt, Inc. (ADTX) last traded around $0.52 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ADTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ADTX. Download the app for real-time alerts.
- How can I analyze Aditxt, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.